Neoplasms by Site × Gastrointestinal × Clear all
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Completed
58 enrolled
NCT05297734 2025-03-19

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Stanford University

Phase NA Recruiting
2,996 enrolled
NCT05462717 2024-11-07

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1 Active not recruiting
222 enrolled
NCT04644315 2023-08-07

ALpha-T

Hoffmann-La Roche

Phase 2 Terminated
1 enrolled 5 charts
NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
NCT04949282 2022-12-23

SEPTRALU

Sociedad Española de Medicina Nuclear e Imagen Molecular

Recruiting
5,000 enrolled
NCT03634982 2022-09-01

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Unknown
133 enrolled
NCT05322486 2022-04-11

Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases

State Scientific Centre of Coloproctology, Russian Federation

Unknown
200 enrolled
NCT01966289 2021-03-30

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
18 enrolled
NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
NCT02005965 2018-09-18

MERCURY II

Royal Marsden NHS Foundation Trust

Unknown
542 enrolled
NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Royal Marsden NHS Foundation Trust

Phase 2 Unknown
237 enrolled
NCT01177007 2017-08-28

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Yale University

Phase 2 Completed
50 enrolled 10 charts